CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	KRAS	RS61764370	Predictive	Supports	Resistance	Epithelial Ovarian Cancer	Carboplatin,Paclitaxel	Ratner et al., 2012
B	ERCC5	RS751402	Prognostic	Supports	Poor Outcome	Parietal Lobe Ependymoma		Somers et al., 2015
B	KIT	rs17084733	Diagnostic	Supports	Positive	Acral Lentiginous Melanoma		Godshalk et al., 2011
B	MTHFR	A222V	Predictive	Supports	Sensitivity/Response	Stomach Cancer	Fluorouracil	Huang et al., 2009
B	ABCG2	Q141K	Prognostic	Supports	Better Outcome	Ovarian Cancer		Tian et al., 2012
B	ABCB1	S893T	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Paclitaxel	Gréen et al., 2006
B	ERCC2	K751Q	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Carboplatin,Paclitaxel	Gandara et al., 2009
B	TYMS	3TRP/3TRP genotype	Predictive	Supports	Resistance	Colorectal Cancer	Irinotecan,Fluorouracil	Martinez-Balibrea et al., 2010
D	LRP1B	Exon 12-22 Deletion	Predictive	Supports	Resistance	Ovarian Cancer	Doxorubicin	Cowin et al., 2012
B	FGFR1	Amplification	Prognostic	Supports	Poor Outcome	Lung Squamous Cell Carcinoma		Seo et al., 2014
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Onartuzumab	Catenacci et al., 2011
B	CDKN2A	p16 Expression	Predictive	Does Not Support	Resistance	Head And Neck Squamous Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Vermorken et al., 2014
B	CDKN2A	p16 Expression	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Panitumumab	Vermorken et al., 2013
C	HRAS	G13D	Predictive	Supports	Resistance	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Boidot et al., 2016
D	HRAS	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Everolimus,Binimetinib,Mirdametinib,Selumetinib,MTOR Kinase Inhibitor AZD8055	Kiessling et al., 2015
B	CD274	Expression	Prognostic	Supports	Better Outcome	Lung Squamous Cell Carcinoma		Schmidt et al., 2015
B	CD274	Expression	Prognostic	Supports	Better Outcome	Ovarian Serous Carcinoma		Darb-Esfahani et al., 2016
C	MTOR	Mutation	Predictive	Supports	Sensitivity/Response	Bladder Carcinoma	Pazopanib,Everolimus	Wagle et al., 2014
B	AKT2	EXPRESSION	Predictive	Supports	Sensitivity/Response	Breast Cancer	Trastuzumab	Grell et al., 2012
C	AKT1	E17K	Predictive	Supports	Sensitivity/Response	Breast Cancer	Capivasertib	Davies et al., 2015
D	PIK3CA	E545K	Predictive	Supports	Sensitivity/Response	Breast Cancer	Akt Inhibitor MK2206,Pictilisib	Beaver et al., 2013
B	MTOR	Mutation	Prognostic	Supports	Poor Outcome	Melanoma		Kong et al., 2016
D	MTOR	H1968Y	Predictive	Supports	Sensitivity/Response	Melanoma	PI3K/BET Inhibitor LY294002,Capivasertib	Kong et al., 2016
C	PTEN	Loss	Predictive	Supports	Sensitivity/Response	Cancer	Paclitaxel,Carboplatin,Buparlisib	Hyman et al., 2015
C	NF2	K159fs	Predictive	Supports	Sensitivity/Response	Breast Cancer	Temsirolimus	Moulder et al., 2015
D	SMAD4	Underexpression	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Cetuximab	Cheng et al., 2015
D	MTOR	P2213S	Predictive	Supports	Sensitivity/Response	Melanoma	Capivasertib,PI3K/BET Inhibitor LY294002	Kong et al., 2016
D	PAPSS1::BRAF	Fusion	Predictive	Supports	Resistance	Melanoma	Vemurafenib	Hutchinson et al., 2013
D	PAPSS1::BRAF	Fusion	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib	Hutchinson et al., 2013
D	TRIM24::BRAF	Fusion	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib	Hutchinson et al., 2013
B	NT5E	Overexpression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Cushman et al., 2015
D	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	GSK321	Okoye-Okafor et al., 2015
C	MET	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Crizotinib	Ou et al., 2011
D	MET	Exon 14 Skipping Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Crizotinib	Togashi et al., 2015
B	EGFR	Overexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Park et al., 2015
C	PIK3CA	P471L	Predictive	Supports	Sensitivity/Response	Merkel Cell Carcinoma	Idelalisib	Shiver et al., 2015
B	RIT1	OVEREXPRESSION	Prognostic	Supports	Poor Outcome	Endometrial Cancer		Xu et al., 2015
D	RIT1	Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Selumetinib,Pictilisib	Berger et al., 2014
D	MYCN	Amplification	Predictive	Supports	Sensitivity/Response	Neuroblastoma	FACT Complex-targeting Curaxin CBL0137	Carter et al., 2015
C	SMO	D473H	Predictive	Supports	Resistance	Medulloblastoma	Vismodegib	Yauch et al., 2009
D	SYK	OVEREXPRESSION	Predictive	Supports	Resistance	Ovarian Cancer	Paclitaxel	Yu et al., 2015
B	CDKN2A	p16 Expression	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Panitumumab	Vermorken et al., 2013
D	SMO	D473H	Predictive	Supports	Resistance	Basal Cell Carcinoma	Vismodegib	Atwood et al., 2015
D	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	AKTi-1/2	She et al., 2008
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Neratinib	Burstein et al., 2010
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Rociletinib	Walter et al., 2013
C	EML4::ALK	Fusion AND ALK G1269A	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Kim et al., 2013
C	EML4::ALK	Fusion AND ALK Amplification	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Doebele et al., 2012
D	PIK3CA	Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cabozantinib	Song et al., 2015
D	NRG1	Expression	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Seribantumab	Sheng et al., 2010

Page 30 of 96

Previous Next